SYNCOMFSyncom Formulations (India) Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers its pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, liquids orals, and effervescent. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SYNCOMF — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Profit growth: 23.8% YoY
- • ROE: 18.4%
- • ROCE: 17.0%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 3-month return: +54.9%
Bull case
- • Profit growth: 23.8% YoY
- • ROE: 18.4%
- • ROCE: 17.0%
- • Price vs SMA200: above
Bear case
- • Revenue growth: 7.4% YoY
- • Dividend yield: 0.00%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Revenue growth: 7.4% YoY
- • Dividend yield: 0.00%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹1.54). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.